People: Antares Pharma Inc (ATRS.PH)

Summary

Name	Age	Since	Current Position
Leonard Jacob	63	2008	Independent Chairman of the Board
Paul Wotton	51	2008	President, Chief Executive Officer, Director
Robert Apple	45	2009	Chief Financial Officer, Executive Vice President, President - Parenteral Products Division
Kaushik Dave	50	2011	Executive Vice President - Product Development
Peter Sadowski	64	2009	Senior Vice President, Chief Technology Officer
Thomas Garrity	63	2003	Independent Director
Jacques Gonella	70	2008	Independent Director
Anton Gueth	55	2003	Independent Director
Eamonn Hobbs	53	2009	Independent Director
Rajesh Shrotriya	68	2004	Independent Director

» Insider Trading

Biographies

Name	Description
Leonard Jacob	Dr. Leonard S. Jacob M.D., Ph.D., is Independent Chairman of the Board of Antares Pharma Inc since October 2008. Dr. Jacob joined the Board of Directors in January 2007 and is the Chairman of Governance and Nominating Committee and is a member of Compensation Committee. In 2006, Dr. Jacob was named Chairman of the Board of Bradley Pharmaceuticals which was subsequently acquired by Nycomed. He founded InKine Pharmaceutical Company Inc. in 1997 and served as Chairman and CEO from its founding until the company was acquired by Salix Pharmaceuticals in 2005. In 1989, Dr. Jacob co-founded Maganin Pharmaceuticals and served as its Chief Operating Officer until 1996. From 1980 to 1989, Dr. Jacob served in a variety of executive roles including Worldwide Vice President of SmithKline & French Labs (now Glaxo-SmithKline) and as a member of their Corporate Management Committee. He earned a Ph.D. in pharmacology from Temple University School of Medicine and an M.D. from the Medical College of Pennsylvania (Drexel University College of Medicine). Dr. Jacob currently serves as Chairman of Life Science Advisors, a consulting group to the healthcare industry. He also serves on the Board of Directors of QuiqMeds, a private drug wholesaler dispensing company, the Colon Cancer Alliance and the Board of Overseers for Temple University School of Medicine and he was a founding Director of the Jacob Internet fund, a public mutual fund where he served from 1999 to 2010.
Paul Wotton	Dr. Paul K. Wotton, Ph.D., is President, Chief Executive Officer and Director of Antares Pharma Inc. Dr. Wotton joined Antares as President and Chief Operating Officer in July 2008 and was appointed Chief Executive Officer in October 2008. Dr. Wotton was appointed to the Board of Directors of Antares in August 2004. Dr. Wotton formerly served as President and CEO of Topigen Pharmaceuticals, Inc., a biotechnology company based in Montreal, Canada. Dr. Wotton possesses over twenty years of experience in the pharmaceutical industry. Prior to joining Topigen, he was Head of Global Business Development at SkyePharma. Dr. Wotton also previously served as Vice President of Corporate Development for Eurand and Vice President of Business Development for Penwest Pharmaceuticals Co. He earned a Bachelor’s Degree in Pharmacy from the University of London, an MBA from Kingston Business School and a Ph.D. in pharmaceutical science from the University of Nottingham.
Robert Apple	Mr. Robert F. Apple CPA., is Chief Financial Officer, Executive Vice President, President -Parenteral Products Division of Antares Pharma Inc. He joined the Company in February 2006 as Senior Vice President, Chief Financial Officer and Corporate Secretary. Prior to joining the Company, Mr. Apple served as Chief Operating and Financial Officer at InKine Pharmaceutical Company, Inc. from 2003 to 2005, and Chief Financial Officer from 1997 to 2002. From 1995 to 1997, Mr. Apple was employed by Genaera Corporation, Inc., a biotechnology company, where he held the position of Corporate Controller. From May 1994 until July 1995, Mr. Apple was employed by Liberty Technologies, Inc. as Corporate Controller. Prior to May 1994, Mr. Apple held various positions of increasing responsibility at Arthur Andersen & Company LLP. He holds a B.A. degree in accounting from Temple University and is a CPA.
Kaushik Dave	Dr. Kaushik J. Dave, Ph.D, is Executive Vice President - Product Development of Antares Pharma Inc. He joined the Company in March 2008 as Vice President of Clinical and Regulatory Affairs. Prior to joining the Company, Dr. Dave was Executive Director Clinical, Regulatory Affairs, Quality Compliance and Program Management at Transave Inc. Prior to that Dr. Dave was employed at Palatin as Vice President Product Development. Prior to working at Palatin, Dr. Dave was employed at Schering-Plough from 1997 to 2001 and Merck from 1990 to 1996. Dr. Dave received his pharmacy degree from University of Bath, UK and Ph.D. in Pharmaceutical Chemistry from University of Kansas. Dr. Dave also received an M.B.A. degree from the Wharton School of the University of Pennsylvania.
Peter Sadowski	Dr. Peter Sadowski, Ph.D. is Senior Vice President, Chief Technology Officer of Antares Pharma Inc. He joined the Company in March 1994 as Vice President, Product Development and has been promoted on various occasions since that time. From October 1992 to February 1994, Dr. Sadowski served as Manager, Product Development for GalaGen, Inc., a biopharmaceutical company. From 1988 to 1992, he was Vice President, Research and Development for American Biosystems, Inc., a medical device company. Dr. Sadowski holds a Ph.D. in microbiology from the University of Minnesota.
Thomas Garrity	Mr. Thomas J. Garrity is Independent Director of Antares Pharma Inc. He serves as Chairman of Audit Committee and as a member of Governance and Nominating Committee. He was Executive Vice President and Chief Financial Officer for PCS Health Systems, a provider of managed pharmaceutical care, from 1994 to 2000. He played a key role during its subsequent integration with Advance Paradigm, Inc. and became Executive Vice President of Financial Operations for the resultant entity, AdvancePCS, a provider of health improvement solutions. Prior to that, Mr. Garrity held various positions at Eli Lilly and Company, including Director of Public Policy Planning and Development; Director of Corporate Financial Planning; and other international, marketing and financial positions. Mr. Garrity holds a B.S. degree from the Massachusetts Institute of Technology in aerospace engineering and an MBA in finance from the University of Chicago. He is currently a private investor and consultant.
Jacques Gonella	Dr. Jacques Gonella Ph.D., is Independent Director of Antares Pharma Inc. Dr. Gonella served as the Chairman of the Board of Directors from January 2001 to October 2008 and is a member of Governance and Nominating Committee. Dr. Gonella was the founder of Permatec (a Swiss company that was merged with Medi-Ject, Inc., to form Antares Pharma, Inc.) and served as the Chairman of the Board of Directors of Permatec since its founding in June 1997. Prior to founding Permatec, Dr. Gonella founded JAGO Pharma AG in 1983 and served as its President and Chief Executive Officer until its acquisition in May 1996 by SkyePharma, PLC, a United Kingdom company listed on the London Stock Exchange and quoted on Nasdaq (“SkyePharma”). Prior to the founding of JAGO, Dr. Gonella occupied various positions with F. Hoffman-La Roche Ltd. and Pfizer Inc. between 1968 and 1979. Dr. Gonella served as a member of the board of directors of Protherics PLC, London from January 2007 to December 2008 and currently sits on the board of directors of several private pharmaceutical companies and pharmaceutical investment funds. He holds a doctorate in analytical chemistry from the Polytechnic Institute of Lausanne, Switzerland. He is currently a private investor and proprietor of JG Consulting AG.
Anton Gueth	Mr. Anton G. Gueth is Independent Director of Antares Pharma Inc. He serves as Chairman of Compensation Committee and as a member of Audit Committee and Governance and Nominating Committee. Mr. Gueth is currently President of Gueth Consulting, which focuses on business development and alliance management in the pharmaceutical industry. He was previously a Managing Director of Burrill & Company, a merchant bank specialized in the health care field. His career includes nearly 19 years with Eli Lilly and Company (“Lilly”), most recently as director of Alliance Management. He also served as General Manager of Lilly’s African and Middle Eastern operations; Vice President of Financial Planning and Treasury of PCS Health Systems; Managing Director of Lilly’s Saudi Arabia, Gulf and Yemen operations, as well as other sales, marketing and financial positions. Mr. Gueth earned a Masters Degree in agricultural economics from the Justus Liebig University in Giessen, Germany, as well as a Masters Degree in public affairs from Indiana University. Mr. Gueth is a director of the American Liver Foundation, Northern California Chapter.
Eamonn Hobbs	Mr. Eamonn P. Hobbs is Independent Director of Antares Pharma Inc. He is a member of Audit Committee and Governance and Nominating Committee. Mr. Hobbs has over 30 years experience in the medical device and combination products industry, including the medical specialty fields of interventional radiology, vascular surgery, interventional cardiology, surgical oncology and gastroenterology. Mr. Hobbs is currently the President and Chief Executive Officer of Delcath Systems, Inc., a specialty pharmaceutical and medical device public company specializing in cancer treatment. Prior to joining Delcath Systems, Inc., Mr. Hobbs served as President and Chief Executive Officer of AngioDynamics, Inc., a company he co-founded in 1988 which has grown into a medical technology public company with a diverse product line. Throughout his 21 year tenure there, he led its efforts in marketing, strategic planning, product development and general management. Before joining AngioDynamics, Mr. Hobbs was Director of Marketing and Product Development at NAMIC; founder, President and Chief Executive Officer of Hobbs Medical, Inc; and a Product Development Engineer at Cook Incorporated. Mr. Hobbs received a Bachelor of Science in Plastics Engineering with a Biomaterials emphasis at the University of Massachusetts (Lowell). Mr. Hobbs also serves as Chairman of the Board of Directors of Cappella Cardiovascular Innovations, Incorporated, and is Chairman of the Board of Directors of the Medical Device Manufacturers Association.
Rajesh Shrotriya	Dr. Rajesh C. Shrotriya MD, is Independent Director of Antares Pharma Inc. He is a member of Compensation Committee and Governance and Nominating Committee. Dr. Shrotriya is the Chairman, Chief Executive Officer and President of Spectrum Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, clinical development and commercialization of oncology drugs. In September 2000, Dr. Shrotriya joined NeoTherapeutics, Inc., as President and Chief Operating Officer, and in August 2002, he was appointed Chief Executive Officer. In this capacity, he spearheaded changes in business strategy and coordinated the structural reorganization of NeoTherapeutics, culminating in the formation of Spectrum Pharmaceuticals, Inc. Prior to that, Dr. Shrotriya was Executive Vice President and Chief Scientific Officer for SuperGen, Inc., and Vice President, Medical Affairs and Vice President, Chief Medical Officer of MGI Pharma, Inc. For 18 years, he held various positions at Bristol-Myers Squibb Company, the most recent being Executive Director Worldwide CNS Clinical Research. Dr. Shrotriya has also held various positions at Hoechst Pharmaceuticals and was an attending physician and held a courtesy appointment at St. Joseph Hospital in Stamford, Connecticut. Dr. Shrotriya received a Bachelor of Medicine and Bachelor of Surgery degree at the Armed Forces Medical College in Poona, India; a post-graduate diploma in Chest Diseases from Delhi University; and a post-graduate M.D. degree from the Grant Medical College in Bombay, India. He also received a certificate for Advanced Biomedical Research Management from Harvard University.

Basic Compensation

Name	Fiscal Year Total
Leonard Jacob	--
Paul Wotton	1,166,630
Robert Apple	731,669
Kaushik Dave	683,161
Peter Sadowski	467,994
Thomas Garrity	--
Jacques Gonella	--
Anton Gueth	--
Eamonn Hobbs	--
Rajesh Shrotriya	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
Leonard Jacob	0	0
Paul Wotton	0	0
Robert Apple	0	0
Kaushik Dave	0	0
Peter Sadowski	285,923	13,915
Thomas Garrity	0	0
Jacques Gonella	0	0
Anton Gueth	0	0
Eamonn Hobbs	0	0
Rajesh Shrotriya	0	0

Insider Trading

Name	Shares Traded	Price
WOTTON PAUL K	10,000	$0.50
DAVE KAUSHIK J	12,000	$0.47
APPLE ROBERT F	10,000	$0.47
DAVE KAUSHIK J	12,000	$4.02
APPLE ROBERT F	10,000	$4.02
WOTTON PAUL K	10,000	$4.04
APPLE ROBERT F	25,000	$4.01
APPLE ROBERT F	25,000	$0.47
WOTTON PAUL K	25,000	$0.50
WOTTON PAUL K	25,000	$4.01
GONELLA JACQUES	5,000	$1.50
WOTTON PAUL K	25,000	$0.50
APPLE ROBERT F	25,000	$0.47
WOTTON PAUL K	25,000	$4.00
APPLE ROBERT F	25,000	$4.00
JACOB LEONARD S	10,000	$3.44
GARRITY THOMAS JOHN	1,250	$1.40
GARRITY THOMAS JOHN	1,000	$0.90
GARRITY THOMAS JOHN	1,000	$1.33
GARRITY THOMAS JOHN	2,000	$1.01
GARRITY THOMAS JOHN	188	$3.97
GARRITY THOMAS JOHN	31,000	$4.02
GARRITY THOMAS JOHN	227	$3.97
GARRITY THOMAS JOHN	220	$3.97
GARRITY THOMAS JOHN	335	$3.97

» Full list on Insider Trading

People: Antares Pharma Inc (ATRS.PH)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: